cybrd1 Antibody

What Are the Primary Applications and Technical Considerations for CYBRD1 Antibodies in Research?

CYBRD1 antibodies are primarily used in Western blot (WB) and immunohistochemistry (IHC) to study iron metabolism, cancer biology, and cellular redox processes. Key technical considerations include:

Western Blot Optimization

• Dilution: Proteintech’s 26735-1-AP antibody is recommended at 1:500–1:3000 for WB, while Abcam’s ab28758 (anti-C-terminus) requires optimization based on sample type .

• Molecular Weight Discrepancies: Observed CYBRD1 bands range from 25–35 kDa (monomer) to 60–70 kDa (dimer), likely due to post-translational modifications or alternative splicing .

IHC Protocol

• Antigen Retrieval: Use TE buffer (pH 9.0) or citrate buffer (pH 6.0) for human tissue samples, such as breast or lung cancer .

• Dilution: Proteintech’s antibody is effective at 1:200–1:800, while Abcam’s ab28758 is validated for IHC-P .

Cross-Reactivity

• Species: Proteintech’s antibody shows reactivity with human, mouse, and pig, while Abcam’s ab28758 is human-specific .

Critical Controls

• Functional Validation: Use RNA interference (RNAi) or CRISPR-Cas9 to confirm CYBRD1’s role in iron metabolism, as antibody-based studies alone may lack specificity .

• Alternative Reductases: Consider compensatory mechanisms involving other iron reductases (e.g., DMT1, SLC40A1) .

Pathway Analysis

• Hepcidin/Ferroportin Regulation: Northern blot analysis of Slc40a1 (ferroportin) and Hamp (hepcidin) mRNA can clarify systemic iron regulation in CYBRD1-deficient models .

What Methodological Approaches Are Recommended for Validating CYBRD1 Antibody Specificity?

Antibody validation is critical to avoid false positives. Below are recommended strategies:

Case Study: Ovarian Cancer Prognostics

In a 2021 study, high CYBRD1 expression correlated with poor survival outcomes in ovarian cancer. Researchers employed IHC with a 1:500 dilution and semiquantitative scoring to validate clinical relevance .

How Does CYBRD1 Upregulation in Cancer Influence Experimental Design for Prognostic Biomarker Studies?

CYBRD1 overexpression in ovarian cancer predicts advanced FIGO stages and lymph node metastasis . To investigate its role as a biomarker:

What Are the Implications of CYBRD1’s Dual Role in Iron Metabolism and Ascorbate Regeneration for Redox Studies?

CYBRD1 reduces Fe³⁺ → Fe²⁺ using ascorbate as an electron donor and may regenerate monodehydroascorbate . This dual function necessitates:

Controlled Experimental Conditions

• Ascorbate Depletion: Treat cells with sodium ascorbate oxidase to isolate CYBRD1’s iron-reducing activity .

• pH Sensitivity: Optimize buffer conditions, as CYBRD1 activity may vary with cellular compartment pH .

Cross-Pathway Analysis

• Ferroptosis Markers: Measure GPX4 and ACSL4 expression to link CYBRD1-driven iron flux to lipid peroxidation .

• ERK Signaling: Assess p-ERK levels to evaluate CYBRD1’s role in oncogenic signaling .

How Can Researchers Address Antibody Cross-Reactivity in Species with Limited CYBRD1 Data?

For understudied species (e.g., pig), validate antibody specificity using:

Ortholog Identification

• GenBank/UniProt: Align target epitopes (e.g., aa 250–C-terminus for Abcam’s antibody) against species-specific CYBRD1 sequences .

Western Blot Controls

• Positive Controls: Use human COLO 320 cells (known CYBRD1 expressers) to confirm cross-reactivity .

• Negative Controls: Include non-transfected cells to rule out nonspecific binding .

What Advanced Techniques Can Clarify CYBRD1’s Subcellular Localization and Interaction Partners?

To resolve CYBRD1’s localization and functional partners:

Immunoelectron Microscopy (IEM)

• Brush-Border Membrane: Confirm CYBRD1’s localization in enterocytes using anti-CYBRD1 conjugated to gold nanoparticles .

Protein Interaction Studies

• Co-IP/MS: Identify partners like ferroportin (SLC40A1) or hepcidin-binding proteins .

How Do Recent Findings on CYBRD1 in Airway Epithelial Cells Influence Respiratory Disease Research?

CYBRD1 may act as a ferrireductase in airway cells, suggesting its role in inflammatory lung diseases . Researchers should:

Model Selection

• In Vitro: Use primary airway epithelial cells or Calu-3 cell lines to study CYBRD1’s iron-regulatory role.

• In Vivo: Evaluate Cybrd1 knockout mice under hypoxic or iron-deficient conditions .

Biomarker Potential

• Sputum Analysis: Measure CYBRD1 levels in sputum samples to correlate with asthma or COPD severity .

What Are the Challenges in Interpreting CYBRD1 Expression in Heterogeneous Tumor Microenvironments?

In ovarian cancer, CYBRD1 expression correlates with tumor-infiltrating immune cells (e.g., Tregs, mast cells) but inversely with CD56 bright NK cells . To address heterogeneity:

Spatial Transcriptomics

• Multispectral Imaging: Map CYBRD1 expression alongside immune markers using multiplex IHC .

Single-Cell RNA-seq

• Cellular Subtypes: Identify CYBRD1-positive subpopulations (e.g., cancer-associated fibroblasts) to refine therapeutic targets .

How Can Researchers Leverage Public Databases (e.g., TCGA) for CYBRD1-Driven Hypothesis Generation?

The Cancer Genome Atlas (TCGA) provides RNA-seq and clinical data to analyze CYBRD1’s role in oncogenesis. Example workflows:

Case Study: Ovarian Cancer

A 2021 TCGA analysis linked high CYBRD1 expression to poor OS (HR = 1.8, P < 0.05) and ERK pathway activation .